The company is banking on revenue from its Sanofi deal and vaccines in development ... 2024 Healthcare & ...

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

Sanofi encountered a backlash in France when ... subject to particular conditions or even vetoed completely. A bid by Canada’s Alimentation Couche-Tard Inc. for supermarket chain Carrefour ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or EoE, ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...